Loomis Sayles & Co. L P Grows Holdings in Haemonetics Co. (NYSE:HAE)

Loomis Sayles & Co. L P boosted its position in shares of Haemonetics Co. (NYSE:HAE - Free Report) by 8.1% during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 163,856 shares of the medical instruments supplier's stock after purchasing an additional 12,310 shares during the period. Loomis Sayles & Co. L P owned about 0.33% of Haemonetics worth $13,171,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Royce & Associates LP boosted its stake in shares of Haemonetics by 2.6% during the third quarter. Royce & Associates LP now owns 1,210,546 shares of the medical instruments supplier's stock valued at $97,304,000 after purchasing an additional 30,868 shares during the period. Thrivent Financial for Lutherans lifted its position in Haemonetics by 29.5% during the third quarter. Thrivent Financial for Lutherans now owns 1,100,183 shares of the medical instruments supplier's stock valued at $88,433,000 after acquiring an additional 250,833 shares during the last quarter. Dimensional Fund Advisors LP lifted its position in Haemonetics by 6.3% during the second quarter. Dimensional Fund Advisors LP now owns 978,735 shares of the medical instruments supplier's stock valued at $80,972,000 after acquiring an additional 57,665 shares during the last quarter. Westfield Capital Management Co. LP boosted its stake in Haemonetics by 10.9% in the third quarter. Westfield Capital Management Co. LP now owns 823,663 shares of the medical instruments supplier's stock valued at $66,206,000 after acquiring an additional 80,783 shares in the last quarter. Finally, Boston Trust Walden Corp grew its holdings in Haemonetics by 13.8% in the third quarter. Boston Trust Walden Corp now owns 809,608 shares of the medical instruments supplier's stock worth $65,076,000 after purchasing an additional 98,019 shares during the last quarter. 99.67% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

A number of research firms have recently weighed in on HAE. Citigroup lowered their price objective on Haemonetics from $94.00 to $85.00 and set a "neutral" rating for the company in a research report on Thursday, August 22nd. BTIG Research started coverage on Haemonetics in a report on Tuesday, September 10th. They issued a "buy" rating and a $112.00 price target for the company. Needham & Company LLC restated a "buy" rating and set a $112.00 price target on shares of Haemonetics in a research note on Friday, November 15th. Raymond James raised shares of Haemonetics from an "outperform" rating to a "strong-buy" rating and set a $120.00 price objective for the company in a research report on Friday, November 8th. Finally, CL King began coverage on shares of Haemonetics in a research report on Friday, September 13th. They set a "buy" rating and a $116.00 target price on the stock. Three analysts have rated the stock with a hold rating, five have issued a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, Haemonetics currently has an average rating of "Moderate Buy" and an average price target of $107.88.

Haemonetics Stock Up 0.1 %

HAE stock opened at $88.56 on Wednesday. The company has a market capitalization of $4.45 billion, a P/E ratio of 36.75, a price-to-earnings-growth ratio of 1.37 and a beta of 0.32. Haemonetics Co. has a 12 month low of $70.25 and a 12 month high of $97.97. The firm's fifty day simple moving average is $79.23 and its 200-day simple moving average is $82.24. The company has a debt-to-equity ratio of 1.39, a current ratio of 3.49 and a quick ratio of 2.09.

Haemonetics (NYSE:HAE - Get Free Report) last posted its earnings results on Thursday, November 7th. The medical instruments supplier reported $1.12 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $1.09 by $0.03. The company had revenue of $345.50 million during the quarter, compared to the consensus estimate of $342.57 million. Haemonetics had a net margin of 9.10% and a return on equity of 22.67%. The firm's quarterly revenue was up 8.6% on a year-over-year basis. During the same period in the previous year, the firm posted $0.99 earnings per share. As a group, equities research analysts forecast that Haemonetics Co. will post 4.59 earnings per share for the current year.

Haemonetics Profile

Haemonetics Corporation, a healthcare company, provides suite of medical products and solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system and Donor360 app.